Praxis Precision Medicines (NASDAQ:PRAX – Get Rating)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $16.00 price target on the stock. Separately, William Blair downgraded shares of Praxis Precision Medicines from an “outperform” rating to a “market perform” rating in a […]
Form S-8 Aeglea BioTherapeutics, streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
BRUSSELS (Belgium) and BOSTON, Massachusetts (USA), December 13th, 2022 (22:01 CET) UCB, a global biopharmaceutical company (EURONEXT BRUSSELS: UCB), and Praxis Precision Medicines, Inc.